Adherence to Long-Term Therapies: Evidence for Action

By S. De Geest, E. Sabaté. European Journal of Cardiovascular Nursing, 2003

7,547 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Medication adherence: WHO cares? (2011, methodology): “this lack of adherence is the most important cause of failure to achieve BP control.(1) Failure to achieve BP control significantly increases the risk of MI, stroke, and hospitalization.”
Handbook of Health Psychology (2001, background): “Although ethnicity, like age, is not a consistent predictor of adherence, individuals of ethnic minority groups who are disadvantaged or marginalized consistently show poorer adherence and health outcomes than other groups (Sabaté, 2003).”
2020 International Society of Hypertension Global Hypertension Practice Guidelines. (2020, background): “The etiology of nonadherence to antihypertensive treatment is multifactorial and includes causes associated with the healthcare system, pharmacological therapy, the disease, patients, and their socioeconomic status [74].”
Impact of mHealth Chronic Disease Management on Treatment Adherence and Patient Outcomes: A Systematic Review (2015, neutral): “With an average adherence rate of only 50% among patients with chronic diseases, non-adherence is a serious challenge to chronic disease management [3].”
Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review (2007, background): “It is also noteworthy in the global context: in developed countries, adherence to medication for chronic diseases in general averages only 50% [8].”